SCHEMBL21595593

SCHEMBL21595593

CSC(=Nc1ccccc1F)c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.44
LMNA P02545 3/20 0.40
SMN1; SMN2 Q16637 5/20 0.39
MEN1 O00255 4/20 0.38
MAPT P10636 4/20 0.36
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA4 P22748 1/20 0.35
CA9 Q16790 1/20 0.35
ALDH1A1 P00352 5/20 0.34
NPC1 O15118 5/20 0.34
RAB9A P51151 4/20 0.34
HSD17B10 Q99714 2/20 0.34
HTT P42858 1/20 0.34
CNR2 P34972 1/20 0.34
KDM4E B2RXH2 4/20 0.33
GAA P10253 3/20 0.33
NFKB1 P19838 2/20 0.33
NFKB2 Q00653 2/20 0.33
RELA Q04206 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21595540 0.76 KDM4E (0.44) KMT2ALMNASMN1; SMN2MEN1MAPT
SCHEMBL21595541 0.76 KDM4E (0.44) KMT2ALMNASMN1; SMN2MEN1MAPT
SCHEMBL5831598 0.76 CA1 (0.38) KMT2ALMNASMN1; SMN2MEN1MAPT
SCHEMBL11373651 0.75 KMT2A (0.50) KMT2ALMNASMN1; SMN2MEN1MAPT
SCHEMBL29220708 0.75 GAA (0.46) KMT2ALMNASMN1; SMN2MEN1MAPT
SCHEMBL21595503 0.74 HSP90AA1 (0.43) KMT2ALMNASMN1; SMN2MEN1MAPT
SCHEMBL21595505 0.74 HSP90AA1 (0.43) KMT2ALMNASMN1; SMN2MEN1MAPT
SCHEMBL8396207 0.74 NOS3 (0.43) KMT2ASMN1; SMN2MEN1MAPTCA1
SCHEMBL21595504 0.73 CYP1A2 (0.44) KMT2ASMN1; SMN2ALDH1A1NPC1RAB9A
SCHEMBL21595506 0.73 CYP1A2 (0.44) KMT2ASMN1; SMN2ALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3810597-B1 1,2,4-TRIAZOLE DERIVATIVES AS TANKYRASE INHIBITORS UNIV OSLO HF (NO) 2025-11-26 EP disclosed
US-11926614-B2 1,2,4-triazole derivatives as tankyrase inhibitors OSLO UNIVERSITETSSYKEHUS HF (NO) 2024-03-12 US disclosed
EP-3810597-A1 1,2,4-TRIAZOLE DERIVATIVES AS TANKYRASE INHIBITORS Oslo Universitetssykehus HF (NO) 2021-04-28 EP disclosed
WO-2019243822-A1 1,2,4-TRIAZOLE DERIVATIVES AS TANKYRASE INHIBITORS OSLO UNIVERSITETSSYKEHUS HF (NO) 2019-12-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11926614-B2 1,2,4-triazole derivatives as tankyrase inhibitors GBA3, CBR3, TECR KMT2A 4273/4885LMNA 1564/4885SMN1; SMN2 4006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.